| Document |
Document Title |
|
WO/2018/005781A1 |
Disclosed herein are methods for preparing [(2S,3R)-N-[(2S)-3-(cyclopent- 1-en-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-
hydroxy-3-(4-methoxyphenyl)-2-[(2S)-2-[2-(morpholin-4-yl)ace
tamido]propanamido]propanamide (compound ...
|
|
WO/2017/007790A9 |
The present invention relates to compounds according to Formula (I) or Formula (II), which are potential bone imaging agents and therapeutic agents for treating bone tumors and metastases. Certain compounds labeled with 68Ga displayed ex...
|
|
WO/2017/216576A1 |
The invention relates to difluoro heterocyclic compounds and their medical uses. Compounds of the invention have the general formula (I): wherein each X is identical and forms part of an ethoxyamine basic side chain which includes a 5- o...
|
|
WO/2017/217553A1 |
[Problem] To provide a novel agricultural chemical, and particularly an herbicide. [Solution] An oxime compound represented by formula (1) and an herbicide containing the same. (In formula (1): B represents B-1 or the like; Q represents ...
|
|
WO/2017/215636A1 |
Provided are a diaryl sulphide piperazine compound and a preparation method and a use thereof. In particular, the compound is a compound shown by formula (I), wherein HX is a C10-20 fatty acid or pamoic acid.
|
|
WO/2017/216579A1 |
The invention relates to a heterocyclic compound 1,1'-(((propane-2,2-diylbis(4,1-phenylene))bis(oxy))bis(etha
ne-2,1-diyl))dipyrrolidine and its medical uses, for example as an autophagy inducer.
|
|
WO/2017/212289A1 |
The present invention relates to a method of reducing, cleaving and/or coupling at least one C=O, C-O, C=C or C=N bond of a compound, using a reagent comprising a stannyl cation.
|
|
WO/2017/210527A1 |
The present disclosure provides novel ATX inhibitors, and pharmaceutical compositions comprising said inhibitors, as well as methods of treatment comprising administration of said inhibitors.
|
|
WO/2017/210006A1 |
The present invention provides a novel partially fluorinated piperazine carboxamide compound, and polymer composition comprising the fluorinated compound and a thermoplastic or thermoset polymer. The polymer composition is useful in prep...
|
|
WO/2017/204144A1 |
Provided is a method for amidating a hydroxy ester compound at a high chemical selectivity. The amidation reaction method for a hydroxy ester compound comprises, in the presence of a catalyst containing a compound of a transition metal o...
|
|
WO/2017/201103A1 |
Disclosed herein, inter alia, are compositions and methods for modulating the activity of N-acylethanolamine acid amidase for the treatment of a pathological state, including pain, an inflammatory condition, or a neurodegenerative disorder.
|
|
WO/2017/201161A1 |
The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and me...
|
|
WO/2017/195428A1 |
Provided is a novel compound having a molecular structure represented by general formula 1 [for instance, where R1 is a C1-10 alkyl group, R2 is a C1-12 alkyl group, R3 is a C1-12 alkyl group, R4 through R7 are hydrogen atoms or C1-8 alk...
|
|
WO/2017/193086A1 |
Provided herein are compounds, pharmaceutical compositions and methods of using said compounds, and compositions for the treatment of cancer and other neoplastic disorders.
|
|
WO/2017/187985A1 |
Provided is a dispersant which makes it possible to achieve the repeated dispersion and coagulation of a dispersoid in a dispersion containing the dispersant upon the irradiation of the dispersion with light for a short time. The dispers...
|
|
WO/2017/181004A1 |
The disclosure of a compound of Formula (I) or a pharmaceutically acceptable salt thereof (I) The variables W, R1, R2, R3, and R4 are defined in the disclosure. The disclosure provides a compound or salt of Formula (I) together with a ph...
|
|
WO/2017/177307A1 |
Compounds having a structure of Formula I or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, R3, R11a, R11b, R11c, R11d, and X, are as defined herein, are provided. Uses of such compounds for modulat...
|
|
WO/2017/174382A1 |
The aim of the invention is to improve the cleaning power of detergents and cleaning agents in relation to stains. This is substantially achieved by incorporating N-methylpiperidine group-containing acyl hydrazones.
|
|
WO/2017/170826A1 |
The purpose of the invention is to provide a compound useful in the prevention or treatment of diabetes, obesity, and conditions related thereto. The present invention relates to an enhancing agent for glucagon-like peptide-1 receptor ac...
|
|
WO/2017/167180A1 |
The present invention provides a vortioxetine pamoic acid salt, which includes a crystal form, a solvate or an amorphous substance of the vortioxetine pamoic acid salt. The present invention provides a preparation method and use of the v...
|
|
WO/2017/165822A1 |
A compound, or a stereoisomer, pharmaceutically acceptable salt, or ester thereof, according to formula (III) or according to Table A, a pharmaceutical composition comprising said compound and at least one pharmaceutically acceptable add...
|
|
WO/2017/161524A1 |
Provided is a pyruvate dehydrogenase kinase inhibitor and an application therefor. Specifically provided is a compound Ra-S-S-Rb of formula X or a pharmaceutically acceptable salt thereof, the compound having excellent inhibition of pyru...
|
|
WO/2017/162536A1 |
Prodrugs of vortioxetine are provided
|
|
WO/2017/159484A1 |
[Problem] To provide an agent for inhibiting aggregation of tau and/or amyloid β. [Solution] A compound represented by formula (I) or a salt thereof. This compound is used in therapy, diagnosis, and symptom alleviation and in prevention...
|
|
WO/2017/157882A1 |
The present invention relates to a compound of formula (I), a stereoisomer thereof, an enantiomer thereof, a racemic thereof, or a tautomer thereof as defined in claim 1 (I) the present invention also relates to a compound of formula (I)...
|
|
WO/2017/153748A1 |
The present invention relates inter alia to a compound of formula (I) wherein R1, R2 and R3, are as defined in the specification and to compositions comprising the same and to the use of the compounds and to compositions of the compounds...
|
|
WO/2017/154016A1 |
The present invention relates to novel crystalline polymorphs of 1 -[2-(2,4-dimethyl- phenylsulfanyl)-phenyl] -piperazine hydrobromide represented by the following structural formula- la and process for preparation thereof.
|
|
WO/2017/156222A1 |
The present disclosure relates to compounds of Formula (I), compositions containing the compounds (alone or in combination with other agents), and their use to prevent, mitigate or treat damage induced by ionizing radiation.
|
|
WO/2017/147701A1 |
The present application is directed to compounds of Formula I: (I) compositions comprising these compounds and their uses, for example as medicaments for the treatment of diseases, disorders or conditions mediated or treatable by inhibit...
|
|
WO/2017/148455A1 |
The invention relates to iodinated aromatic choline analogs of general formula wherein at least one R is iodine; the quaternary ammonium group comprises a hydroxyl substituent, and further substituent are as defined in the claims. The co...
|
|
WO/2017/147146A1 |
Described herein are compounds, pharmaceutical compositions and medicaments that include such compounds, and methods of using such compounds to modulate transient receptor potential vanilloid 1 receptor (TRPV1) activity.
|
|
WO/2017/144404A1 |
The invention relates to the manufacture of a compound of formula (I), wherein R1 is defined as in the description and in the claims.
|
|
WO/2017/144181A1 |
The invention relates to a composition comprising a fluorine-containing surfactant having a cationic group, a divalent sulfur-containing group and a fluorinated group, further comprising an anion that corresponds to the cationic group of...
|
|
WO/2017/141512A1 |
Provided is a catalyst represented by general formula (1), where R1-R16 in the general formula (1) individually represent a hydrogen atom or a substituent independently of each other.
|
|
WO/2017/141775A1 |
The present invention relates to a lubricant containing an ionic liquid that has a conjugate base and a conjugate acid, wherein the conjugate acid has a group including a hydroxyl group and a group including a linear hydrocarbon group ha...
|
|
WO/2017/140778A1 |
The present invention relates to compounds of formula (I), and pharmaceutically acceptable salts, solvates and prodrugs thereof: Formula (I) wherein Q is selected from O, S and Se; J is S or Se; W1 and W2, when present, are independently...
|
|
WO/2017/137047A1 |
The invention relates to a method for arylation of amines, such as aliphatic amines by reaction of aryl-halogens, e.g. chloro- or fluorobenzene derivatives without strongly electron withdrawing substituents in the presence of a strong base.
|
|
WO/2017/137048A1 |
The invention relates to a method for synthesis of 1-[2-(2,4-Dimethyl-phenylsulfanyl)- phenyl]piperazine in the presence of a strong base.
|
|
WO/2017/137530A1 |
The present invention relates to a process to prepare ethyleneamines of the formula NH2-(C2H4-NH-)pH wherein p is at least 2 wherein one or more units -NH-C2H4-NH- are present as a piperazine unit or precursors thereof wherein optionally...
|
|
WO/2017/133591A1 |
The present invention discloses an N-sulfonyl benzamide derivative with a heterocyclic substituent, and a preparation method therefor and a pharmaceutical application thereof. More specifically, the invention discloses a compound represe...
|
|
WO/2017/133913A1 |
The present invention relates to a process for the N-alkylation of amines by reacting an amine with an orthocarboxylic acid ester and with hydrogen in the presence of a hydrogenation catalyst.
|
|
WO/2017/133429A1 |
The present invention discloses a terpineol and a preparation method and an application thereof. The terpineol has a structure represented by formulas (I) or (II). In formula (I), R is independently selected from C12 to C16 alkyl, -NR1R2...
|
|
WO/2017/129061A1 |
Disclosed is an application of substituted cinnamamide derivatives in the preparation of Anti-anxiety medications, the substituted cinnammide derivatives are compounds having the structure of formula (I) or pharmaceutically acceptable sa...
|
|
WO/2017/125673A1 |
The invention relates to a method for preparing a compound (I) or one of the salts thereof, and the uses of said method, R1OOC-C(=X)-CHR2 R3 (I), wherein X is selected among O; N-R', wherein R' is H or a C1-C6 alkyl; and N-OR'' wherein R...
|
|
WO/2017/125504A1 |
The present invention provides novel polymorphic forms of vortioxetine hydrobromide (I).
|
|
WO/2017/122697A1 |
The present invention provides a radiation-sensitive resin composition that contains: a first polymer having a first structural unit that contains a first acid-dissociable group; a radiation-sensitive acid generator; and a compound repre...
|
|
WO/2017/119515A1 |
An object of the present invention is to provide a novel ascochlorin derivative which activates adenosine monophosphate-activated protein kinase (AMPK), and is useful in the treatment or prevention of diseases or conditions that involve ...
|
|
WO/2017/112972A1 |
The invention relates to a method for producing ionic liquids based on bistriflimid anion. In a first stage, a primary aliphatic amine R-NH2 is reacted with triflic anhydride Tf2O so as to form corresponding N-alkylated triflic imid R-NT...
|
|
WO/2017/116272A1 |
The invention relates to the field of the organic chemistry and, in particular to a method for preparing a compound of formula (I) or (II), and/or a mixture of isomers thereof, wherein R is -Alk, -AlkN(Alk)2, -AlkN(Ar)2, -AlkNAlkAr, -Alk...
|
|
WO/2017/114497A1 |
Provided are the use of LSD1 inhibitors in connection with use and manufacture of immune effector cells (e.g., T cells, NK cells), e.g., engineered to express a chimeric antigen receptor (CAR), to treat a subject having a disease, e.g., ...
|
